공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

미국의 조제 약국(Compounding Pharmacies) 시장(2021-2027년) : 시장 예측(약국 유형, 무균성 구분, 제품, 용도. 조제 구분, 최종사용자, 치료 구분별), 업계 동향, 성장 잠재성, 가격 동향, 시장 점유율

U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product, By Application, By Compounding Type, By Therapeutic Area, Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

리서치사 Global Market Insights Inc.
발행일 2021년 02월 상품 코드 987844
페이지 정보 영문 85 Pages
가격
US $ 2,850 ₩ 3,221,000 Unprintable PDF (Single User License)
US $ 4,850 ₩ 5,481,000 Printable PDF (Multi User License)
US $ 6,850 ₩ 7,742,000 Printable PDF (Enterprise User License)


미국의 조제 약국(Compounding Pharmacies) 시장(2021-2027년) : 시장 예측(약국 유형, 무균성 구분, 제품, 용도. 조제 구분, 최종사용자, 치료 구분별), 업계 동향, 성장 잠재성, 가격 동향, 시장 점유율 U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product, By Application, By Compounding Type, By Therapeutic Area, Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027
발행일 : 2021년 02월 페이지 정보 : 영문 85 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

미국의 조제 약국 시장은 향후 몇 년간 급성장을 나타낼 것으로 예측됩니다. 고령자의 조제 제품 이용 증가, 정제와 시럽 수요 증가, 호르몬 보충 필요성 증대, 아날로그 X선 시스템 선호 경향, 비경구제, 점안제 등의 무균 조제 도입 확대 등의 요인이 시장 성장에 기여할 전망입니다.

약국 구분별로는 503A 부문이 2020년 40% 이상의 점유율을 보였고, 앞으로도 강력한 성장을 나타낼 것으로 예측됩니다. 의료 전문가가 아날로그 X선 시스템을 선호하는 경향 등의 요인이 503A 부문의 성장을 가속하고 있습니다. 무균성 구분별로는 무균 부문이 2020년 10억 달러 이상 규모를 나타냈고, 앞으로도 강력한 성장세를 보일 전망입니다.

미국의 조제 약국(Compounding Pharmacies) 시장을 조사했으며, 시장의 정의와 개요, 산업의 에코시스템, 코로나(COVID-19) 및 기타 시장 영향요인 분석, 법규제 및 상환 환경, 기술 및 혁신 동향, 시장 규모 추이와 예측, 약국 유형·무균성 구분·제품·용도·조제 구분·최종사용자·치료 구분 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 전해드립니다.

제1장 조사 방법

제2장 개요

제3장 산업 인사이트

  • 산업 분류
  • 산업 상황
  • 산업 영향요인
    • 성장요인
    • 잠재적 위험&과제
  • 성장 가능성
  • COVID-19 : 영향 분석
  • 규제 상황
  • 상환 상황
  • 혁신적 기술
  • Porter의 산업 분석
  • 경쟁 구도
  • PESTEL 분석

제4장 시장 분석과 예측 : 약국 유형별

  • 503A
  • 503B

제5장 시장 분석과 예측 : 무균성 구분별

  • 무균
  • 비무균

제6장 시장 분석과 예측 : 제품별

  • 경구제
    • 고형 제제
    • 액체 제제
  • 국소제
    • 연고
    • 크림
    • 페이스트
    • 기타
  • 경장제
    • 좌약
    • 관장
    • 기타
  • 비경구제
    • 소용량 비경구(SVP) 솔루션
    • 대용량 비경구(LVP) 솔루션
  • 비강분무제
  • 점안제
  • 이용

제7장 시장 분석과 예측 : 용도별

  • 소아
  • 성인
  • 고령자
  • 수의

제8장 시장 분석과 예측 : 조제 유형별

  • Pharmaceutical Ingredient Alteration(PIA)
  • Currently Unavailable Pharmaceutical Manufacturing(CUPM)
  • Pharmaceutical Dosage Alteration(PDA)
  • 기타

제9장 시장 분석과 예측 : 치료 구분별

  • 호르몬 보충
  • 통증관리
  • 피부과
  • 특수약
  • 식이보충제
  • 기타

제10장 기업 개요

  • Athenex Pharma Solutions(Athenex Inc.
  • B. Braun
  • Dougherty's Pharmacy, Inc
  • Fagron
  • Fresenius Kabi
  • ImprimisRx(Harrow Health, Inc.)
  • Institutional Pharmacy Solutions
  • McGuff Company Inc(McGuff Compounding Pharmacy Services)
  • Pencol Compounding Pharmacy
  • Rx3 Compounding Pharmacy
  • Triangle Compounding Pharmacies
  • US Compounding Inc.
  • Wedgewood Village Pharmacy, Inc.
LSH 21.02.18

Data Tables

  • TABLE 1. U.S. compounding pharmacies industry 360 degree synopsis, 2016 - 2027
  • TABLE 2. U.S. compounding pharmacies market, by pharmacy type, 2016 - 2027 (USD Million)
  • TABLE 3. U.S. compounding pharmacies market, by sterility, 2016 - 2027 (USD Million)
  • TABLE 4. U.S. compounding pharmacies market size, by product, 2016 - 2027 (USD Million)
  • TABLE 5. U.S. compounding pharmacies market size, by oral product, 2016 - 2027 (USD Million)
  • TABLE 6. U.S. compounding pharmacies market size, by oral solid preparation, 2016 - 2027 (USD Mn)
  • TABLE 7. U.S. compounding pharmacies market size, by oral liquid preparation, 2016 - 2027 (USD Mn)
  • TABLE 8. U.S. compounding pharmacies market size, by topical product, 2016 - 2027 (USD Mn)
  • TABLE 9. U.S. compounding pharmacies market size, by rectal product, 2016 - 2027 (USD Mn)
  • TABLE 10. U.S. compounding pharmacies market size, by parenteral product, 2016 - 2027 (USD Mn)
  • TABLE 11. U.S. compounding pharmacies market, by application, 2016 - 2027 (USD Million)
  • TABLE 12. U.S. compounding pharmacies market, by compounding type, 2016 - 2027 (USD Mn)
  • TABLE 13. U.S. compounding pharmacies market, by therapeutic area, 2016 - 2027 (USD Mn)

Charts & Figures

  • FIG. 1 Data validation
  • FIG. 2 U.S. compounding pharmacies industry 360 degree synopsis, 2016-2027
  • FIG. 3 Industry segmentation
  • FIG. 4 U.S. compounding pharmacies market, 2016 - 2027 (USD Million)
  • FIG. 5 Growth potential analysis, by pharmacy type
  • FIG. 6 Growth potential analysis, by sterility
  • FIG. 7 Growth potential analysis, by product
  • FIG. 8 Growth potential analysis, by application
  • FIG. 9 Growth potential analysis, compounding type
  • FIG. 10 Growth potential analysis, therapeutic area
  • FIG. 11 Porter's analysis
  • FIG. 12 Strategy dashboard
  • FIG. 13 PESTEL analysis
  • FIG. 14 Key segment trends, by pharmacy type
  • FIG. 15 Key segment trends, by sterility
  • FIG. 16 Key segment trends, by product
  • FIG. 17 Key segment trends, by application
  • FIG. 18 Key segment trends, by compounding type
  • FIG. 19 Key segment trends, by therapeutic area

Title:
U.S. Compounding Pharmacies Market Size By Pharmacy Type (503A, 503B), By Sterility (Sterile, Non-sterile), By Product (Oral, Topical, Rectal, Parenteral, Nasal, Ophthalmic, Otic), By Application (Paediatric, Adult, Geriatric, Veterinary), By Compounding Type (Pharmaceutical Ingredient Alteration [PIA], Currently Unavailable Pharmaceutical Manufacturing [CUPM], Pharmaceutical Dosage Alteration [PDA]), By Therapeutic Area (Hormone Replacement, Pain Management, Dermatology, Specialty Drugs, Nutritional Supplements), Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027.

The U.S. compounding pharmacies market is forecast to register tremendous gains over the coming years due to increasing product adoption among elderly population base, increasing demand for tablets and syrups, heightening need for hormone replacement, and favorable analog medical X-ray system preference among healthcare professionals. Rising adoption of sterile preparations such as parenteral and ophthalmic dosage forms in treatment of various chronic diseases will drive the market growth.

Generally, the conventional role of compounding pharmacies is to make medicines prescribed by specialists for specific patients with requirements that cannot be met by drugs that are comedically available. As per IACP, there are approximately 56,000 community-based pharmacies across the United States. Nearly half of them directly serve the doctors as well as local patients.

The U.S. compounding pharmacies market is segmented into numerous segments in terms of pharmacy type, sterility, product, application, therapeutic area, and compounding type.

Based on pharmacy type the market for U.S. compounding pharmacies is classified into 503B and 503A. In 2020, 503A segment witnessed more than 40% market share and is estimated to record robust growth over the forthcoming time period. Wide preference of analog medical X-ray systems by healthcare professionals will foster the industry growth.

These types of pharmacies are closely linked to what might be considered as conventional compounding pharmacies.

With respect to sterility the market is divided into non-sterile and sterile. In 2020, sterile segment accounted for more than $1 billion market value and is anticipated to record strong growth over the coming years. This estimated growth is attributed to the rising adoption of sterile preparations such as parenteral and ophthalmic dosage forms in treatment of various chronic diseases.

Based on product the U.S. compounding pharmacies market is categorized into nasal, ophthalmic, parenteral, rectal, topical, oral, and others. Among these, the oral segment will witness around 6% CAGR over the analysis timeframe owing to increasing demand for tablets and syrups.

In terms of application the overall market is bifurcated into veterinary, geriatric, adult, and pediatric. In 2020, geriatric segment held over 19% market share and is slated to witness healthy growth over the coming time period. This anticipated growth is ascribed to the increasing demand for compounding products among elderly population base.

With respect to therapeutic area the U.S. compounding pharmacies market is segmented into nutritional supplements, specialty drugs, dermatology, pain management, hormone replacement, and others. Hormone replacement segment held a market valuation of more than $1 billion in 2020 and is further estimated to witness strong growth over the forecast timeframe.

Many of the bioidentical hormones are mainly available through a prescription by compounding pharmacies. In fact, compounding gives the patients the chance to get customized doses of these hormones.

Based on compounding type, the overall market is classified into PDA (pharmaceutical dosage alteration), CUPM (currently unavailable pharmaceutical manufacturing), PIA (pharmaceutical ingredient alteration), and others. In 2020, the others segment witnessed around 20% market share and is estimated to follow robust growth in the coming years.

Table of Contents

Chapter 1 Methodology

  • 1.1 Methodology
  • 1.2 Base estimates & working
  • 1.3 Forecast calculations
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 U.S. compounding pharmacies industry 360 degree synopsis, 2016 - 2027

Chapter 3 US Compounding Pharmacies Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing geriatric population and improved longevity
      • 3.3.1.2 Growing acceptance of personalized medicines in U.S.
      • 3.3.1.3 Increasing drug shortage in the country
      • 3.3.1.4 Convenience of using compounded drugs
      • 3.3.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Changing regulatory scenario
      • 3.3.2.2 Issues related to safety standards of compounded drugs
  • 3.4 Growth potential analysis
    • 3.4.1 By pharmacy type
    • 3.4.2 By sterility
    • 3.4.3 By product
    • 3.4.4 By application
    • 3.4.5 By compounding type
    • 3.4.6 By therapeutic area
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
  • 3.7 Reimbursement landscape
  • 3.8 Innovative compounding technologies
    • 3.8.1 Web-based quality management system
    • 3.8.2 Digital tools
  • 3.9 Porter's analysis
  • 3.10 Competitive landscape, 2019
    • 3.10.1 Strategy dashboard, 2019
  • 3.11 PESTEL Analysis

Chapter 4 US Compounding Pharmacies Market, By Pharmacy Type

  • 4.1 Key segment trends
  • 4.2 503A
    • 4.2.1 503A market, by country, 2016 - 2027, (USD Million)
  • 4.3 503B
    • 4.3.1 503B market, by country, 2016 - 2027, (USD Million)

Chapter 5 US Compounding Pharmacies Market, By Sterility

  • 5.1 Key segment trends
  • 5.2 Sterile
    • 5.2.1 Sterile market, by country, 2016 - 2027, (USD Million)
  • 5.3 Non-sterile
    • 5.3.1 Non-sterile market, by country, 2016 - 2027, (USD Million)

Chapter 6 US Compounding Pharmacies Market, By Product

  • 6.1 Key segment trends
  • 6.2 Oral
    • 6.2.1 Oral market by country, 2016 - 2027 (USD Million)
    • 6.2.2 Solid preparations
      • 6.2.2.1 Solid preparations market, by country, 2016 - 2027, (USD million)
      • 6.2.2.2 Tablets
        • 6.2.2.2.1 Tablets market, by country, 2016 - 2027, (USD Million)
      • 6.2.2.3 Capsules
        • 6.2.2.3.1 Capsules market, by country, 2016 - 2027, (USD Million)
      • 6.2.2.4 Granules
        • 6.2.2.4.1 Granules market, by country, 2016 - 2027, (USD Million)
      • 6.2.2.5 Powder
        • 6.2.2.5.1 Powder market, by country, 2016 - 2027, (USD Million)
      • 6.2.2.6 Others
        • 6.2.2.6.1 Others market, by country, 2016 - 2027, (USD Million)
    • 6.2.3 Liquid preparations
      • 6.2.3.1 Liquid preparations market, by country, 2016 - 2027, (USD Million)
      • 6.2.3.2 Solutions
        • 6.2.3.2.1 Solutions market, by country, 2016 - 2027, (USD Million)
      • 6.2.3.3 Suspension
        • 6.2.3.3.1 Suspension market, by country, 2016 - 2027, (USD Million)
      • 6.2.3.4 Emulsion
        • 6.2.3.4.1 Emulsion market, by country, 2016 - 2027, (USD Million)
      • 6.2.3.5 Syrup
        • 6.2.3.5.1 Syrup market, by country, 2016 - 2027, (USD Million)
      • 6.2.3.6 Others
        • 6.2.3.6.1 Others market, by country, 2016 - 2027, (USD Million)
  • 6.3 Topical
    • 6.3.1 Topical market, by country, 2016 - 2027, (USD Million)
    • 6.3.2 Ointments
      • 6.3.2.1 Ointments market, by country, 2016 - 2027, (USD Million)
    • 6.3.3 Creams
      • 6.3.3.1 Creams market, by country, 2016 - 2027, (USD Million)
    • 6.3.4 Gels
      • 6.3.4.1 Gels market, by country, 2016 - 2027, (USD Million)
    • 6.3.5 Pastes
      • 6.3.5.1 Pastes market, by country, 2016 - 2027, (USD Million)
    • 6.3.6 Others
      • 6.3.6.1 Others market, by country, 2016 - 2027, (USD Million)
  • 6.4 Rectal
    • 6.4.1 Rectal market by country, 2016 - 2027 (USD Million)
    • 6.4.2 Suppositories
      • 6.4.2.1 Suppositories market, by country, 2016 - 2027, (USD Million)
    • 6.4.3 Enema
      • 6.4.3.1 Enema market, by country, 2016 - 2027, (USD Million)
    • 6.4.4 Others
      • 6.4.4.1 Others market, by country, 2016 - 2027, (USD Million)
  • 6.5 Parenteral
    • 6.5.1 Parenteral market by country, 2016 - 2027 (USD Million)
    • 6.5.2 Small volume parenteral (SVP) solutions
      • 6.5.2.1 Small volume parenteral (SVP) solutions market by country, 2016 - 2027 (USD Million)
    • 6.5.3 Large Volume Parenteral (LVP) Solutions
      • 6.5.3.1 Large Volume Parenteral (LVP) Solutions market by country, 2016 - 2027 (USD Million)
  • 6.6 Nasal
    • 6.6.1 Nasal market by country, 2016 - 2027 (USD Million)
  • 6.7 Ophthalmic
    • 6.7.1 Ophthalmic market by country, 2016 - 2027 (USD Million)
  • 6.8 Otic
    • 6.8.1 Otic market by country, 2016 - 2027 (USD Million)

Chapter 7 US Compounding Pharmacies Market, By Application

  • 7.1 Key segment trends
  • 7.2 Pediatric
    • 7.2.1 Pediatric market, by country, 2016 - 2027, (USD Million)
  • 7.3 Adult
    • 7.3.1 Adult market, by country 2016 - 2027, (USD Million)
  • 7.4 Geriatric
    • 7.4.1 Geriatric market, by country 2016 - 2027, (USD Million)
  • 7.5 Veterinary
    • 7.5.1 Veterinary market, by country 2016 - 2027, (USD Million)

Chapter 8 US Compounding Pharmacies Market, By Compounding Type

  • 8.1 Key segment trends
  • 8.2 Pharmaceutical Ingredient Alteration (PIA)
    • 8.2.1 Pharmaceutical ingredient alteration (PIA) market, by country, 2016 - 2027, (USD Million)
  • 8.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 8.3.1 Currently unavailable pharmaceutical manufacturing (CUPM) market, by country, 2016 - 2027, (USD Million)
  • 8.4 Pharmaceutical Dosage Alteration (PDA)
    • 8.4.1 Pharmaceutical dosage alteration (PDA) market, by country, 2016 - 2027, (USD Million)
  • 8.5 Others
    • 8.5.1 Others market, by country, 2016 - 2027, (USD Million)

Chapter 9 US Compounding Pharmacies Market, By Therapeutic Area

  • 9.1 Key segment trends
  • 9.2 Hormone replacement
    • 9.2.1 Hormone replacement market, by country, 2016 - 2027, (USD Million)
  • 9.3 Pain management
    • 9.3.1 Pain management market, by country, 2016 - 2027, (USD Million)
  • 9.4 Dermatology
    • 9.4.1 Dermatology market, by country, 2016 - 2027, (USD Million)
  • 9.5 Specialty drugs
    • 9.5.1 Specialty drugs market, by country, 2016 - 2027, (USD Million)
  • 9.6 Nutritional supplements
    • 9.6.1 Nutritional supplements market, by country, 2016 - 2027, (USD Million)
  • 9.7 Others
    • 9.7.1 Others market, by country, 2016 - 2027, (USD Million)

Chapter 10 Company Profiles

  • 10.1 Athenex Pharma Solutions (Athenex Inc.)
    • 10.1.1 Business Overview
    • 10.1.2 Financial data
    • 10.1.3 Product landscape
    • 10.1.4 Strategic outlook
    • 10.1.5 SWOT analysis
  • 10.2 B. Braun
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Dougherty's Pharmacy, Inc
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Fagron
    • 10.4.1 Business overview
    • 10.4.2 Financial Data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 Fresenius Kabi
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 SWOT analysis
  • 10.6 ImprimisRx (Harrow Health, Inc.)
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Institutional Pharmacy Solutions
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 SWOT analysis
  • 10.8 McGuff Company Inc (McGuff Compounding Pharmacy Services)
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 SWOT analysis
  • 10.9 Pencol Compounding Pharmacy
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 SWOT analysis
  • 10.10 Rx3 Compounding Pharmacy
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 SWOT analysis
  • 10.11 Triangle Compounding Pharmacies
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 SWOT analysis
  • 10.12 US Compounding Inc.
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 Wedgewood Village Pharmacy, Inc.
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 SWOT analysis
Back to Top
전화 문의
F A Q